Phase 2 study of granulocyte-macrophage colony-stimulating factor plus thalidomide in patients with hormone-naïve adenocarcinoma of the prostate

Urologic Oncology: Seminars and Original Investigations

Volumn 27, Issue 1, 2009, Pages 8-13

  Amato, Robert J ^a   Hernandez McClain, Joan ^a   Henary, Haby ^a  

^a HOUSTON METHODIST RESEARCH INSTITUTE   (United States)

Author keywords

Biochemical relapse; Granulocyte macrophage colony stimulating factor; Prostate carcinoma; Prostate specific antigen; Thalidomide

Indexed keywords

GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; PROSTATE SPECIFIC ANTIGEN; TESTOSTERONE; THALIDOMIDE;

ADULT; AGED; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER GROWTH; CLINICAL ARTICLE; CLINICAL TRIAL; CONSTIPATION; DEEP VEIN THROMBOSIS; DIARRHEA; DRUG DOSE REDUCTION; DRUG EFFICACY; FATIGUE; FEVER; HUMAN; LUNG EMBOLISM; MALE; NEUROPATHY; PERIPHERAL NEUROPATHY; PRIORITY JOURNAL; PROSTATE ADENOCARCINOMA; PROSTATECTOMY; RASH; TINNITUS; TREATMENT DURATION; TREATMENT RESPONSE;

ADENOCARCINOMA; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DRUG SYNERGISM; GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR; HUMANS; MALE; MIDDLE AGED; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; THALIDOMIDE; TREATMENT OUTCOME;

EID: 57849097520     PISSN: 10781439     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.urolonc.2007.10.014     Document Type: Article

References (27)

1. Ward J.F., and Moul J.W. Treating the biochemical recurrence of prostate cancer after definitive primary therapy. Clin Prostate Cancer 4 (2005) 38-44
2. Grossfeld G.D., Stier D.M., Flanders S.C., et al. Use of second treatment following definitive local therapy for prostate cancer: Data from the CaPSURE database. J Urol 160 (1998) 1398-1404
3. Krygiel J.M., Smith D.S., Homan S.M., et al. Intermediate term biochemical progression rates after radical prostatectomy and radiotherapy in patients with screen detected prostate cancer. J Urol 174 (2005) 126-130
4. Boccon-Gibod L., Djavan W.B., Hammerer P., et al. Management of prostate-specific antigen relapse in prostate cancer: A European consensus. Int J Clin Pract 58 (2004) 382-390
5. Lange P.H., Ercole C.J., Lightner D.J., et al. The value of serum prostate specific antigen determination before and after radical prostatectomy. J Urol 141 (1989) 873-879
6. Freedland S.J., Humphreys E.B., Mangold L.A., et al. Risk of prostate cancer-specific mortality following biochemical recurrence after radical prostatectomy. JAMA 294 (2005) 433-439
7. Gronau E., Goppelt M., Harzmann R., et al. Prostate cancer relapse after therapy with curative intention: A diagnostic and therapeutic dilemma. Onkologie 28 (2005) 361-366
8. Prostate Cancer Trialists' Collaborative Group. Maximum androgen blockade in advanced prostate cancer: an overview of the randomized trials. Lancet 355 (2000) 1491-1498
9. Bennett C.L., Tosteson T.D., Schmitt B., et al. Maximum androgen-blockade with medical or surgical castration in advanced prostate cancer: A meta-analysis of nine published randomized controlled trials and 4,128 patients using flutamide. Prostate Cancer Prostatic Dis 2 (1999) 4-8
10. Ferrer F.A., Miller L.J., Andrawis R.I., et al. Angiogenesis and prostate cancer: In vivo and in vitro expression of angiogenesis factors by prostate cancer cells. Urology 51 (1998) 161-167
11. Macpherson G.R., Franks M., Tomoaia-Cotisel A., et al. Current status of thalidomide and its role in the treatment of metastatic prostate cancer. Crit Rev Oncol Hematol 46 (2003) S49-S57
12. Franks M.E., Macpherson G.R., and Figg W.D. Thalidomide. Lancet 363 (2004) 1802-1811
13. Amato R.J., Loughnan M.S., Flynn E., et al. Thalidomide is an inhibitor of angiogenesis. Proc Natl Acad Sci USA 91 (1994) 4082-4085
14. Drake M.J., Robson W., Mehta P., Leung H.Y., et al. An open-label Phase II study of low-dose thalidomide in androgen-independent prostate cancer. Br J Cancer 88 (2003) 822-827
15. Bauer K.S., Dixon S.C., and Figg W.D. Inhibition of angiogenesis by thalidomide requires metabolic activation, which is species-dependent. Biochem Pharmacol 55 (1998) 1827-1834
16. Richardson P., Hideshima T., and Anderson K. Thalidomide: Emerging role in cancer medicine. Annu Rev Med 53 (2002) 629-657
17. Eleutherakis-Papaiakovou V., Bamias A., and Dimopoulos M.A. Thalidomide in cancer medicine. Ann Oncol 15 (2004) 1151-1160
18. Fagerberg J. Granulocyte-macrophage colony-stimulating factor as an adjuvant in tumor immunotherapy. Med Oncol 13 (1996) 155-160
19. Thomas R., and Lipsky P.E. Dendritic cells: Origin and differentiation. Stem Cells 14 (1996) 196-206
20. Small E.J., Reese D.M., Um B., et al. Therapy of advanced prostate cancer with granulocyte macrophage colony-stimulating factor. Clin Cancer Res 5 (1999) 1738-1744
21. Dranoff G., Jaffee E., Lazenby A., et al. Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and long lasting antitumor immunity. Proc Natl Acad Sci USA 90 (1993) 3539-3543
22. Vieweg J., Rosenthal F.M., Bannerji R., et al. Immunotherapy of prostate cancer in the Dunning rat model: Use of cytokine gene modified tumor vaccines. Cancer Res 54 (1994) 1760-1765
23. Figg W.D., Dahut W., Duray P., et al. A randomized Phase II trial of thalidomide, an angiogenesis inhibitor, in patients with androgen-independent prostate cancer. Clin Cancer Res 7 (2001) 1888-1893
24. Dahut W.L., Gulley J.L., Arlen P.M., et al. Randomized Phase II trial of docetaxel plus thalidomide in androgen-independent prostate cancer. J Clin Oncol 22 (2004) 2532-2539
25. Rini B.I., Weinberg V., Bok R., et al. Prostate-specific antigen kinetics as a measure of the biologic effect of granulocyte-macrophage colony-stimulating factor in patients with serologic progression of prostate cancer. J Clin Oncol 21 (2003) 99-105
26. Rini B., Weinberg V., Fong E., et al. Clinical and immunologic characteristics of patients with serologic progression of prostate cancer achieving long-term disease control with GM-CSF. Poster presentation at: American Society of Clinical Oncology 2005 Prostate Cancer Symposium; February 17-19 (2005) Orlando, FL. Abstract 261
27. Dreicer R., Klein E.A., Elson P., et al. Phase II trial of GM-CSF + thalidomide in patients with androgen-independent metastatic prostate cancer. Urol Oncol 23 (2005) 82-86